MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- PANACEA BIOTECH - MYLAN (US)
PANACEA BIOTECH vs MYLAN (US) - Comparison Results
PANACEA BIOTECH Change
Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More
MYLAN (US)
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
Financials
 PANACEA BIOTECH  MYLAN |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| PANACEA BIOTECH Mar-19 |
MYLAN Dec-18 |
PANACEA BIOTECH/ MYLAN |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 354 | 3,495 | - | |
| Low | Rs | 138 | 1,924 | - | |
| Sales per share (Unadj.) | Rs | 74.6 | 1,608.1 | - | |
| Earnings per share (Unadj.) | Rs | 6.7 | 43.7 | - | |
| Cash flow per share (Unadj.) | Rs | 15.5 | 344.8 | - | |
| Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
| Dividend yield (eoy) | % | 0 | 0 | - | |
| Book value per share (Unadj.) | Rs | 57.2 | 1,739.7 | - | |
| Shares outstanding (eoy) | m | 61.25 | 514.50 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 3.3 | 1.7 | 195.8% | |
| Avg P/E ratio | x | 36.8 | 62.0 | 59.3% | |
| P/CF ratio (eoy) | x | 15.9 | 7.9 | 201.9% | |
| Price / Book Value ratio | x | 4.3 | 1.6 | 276.0% | |
| Dividend payout | % | 0 | 0 | - | |
| Avg Mkt Cap | Rs m | 15,061 | 1,393,882 | 1.1% | |
| No. of employees | `000 | 2.3 | 35.0 | 6.6% | |
| Total wages/salary | Rs m | 1,471 | 0 | - | |
| Avg. sales/employee | Rs Th | 1,973.6 | 23,639.1 | 8.3% | |
| Avg. wages/employee | Rs Th | 635.6 | 0 | - | |
| Avg. net profit/employee | Rs Th | 176.8 | 641.9 | 27.5% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 4,567 | 827,370 | 0.6% | |
| Other income | Rs m | 45 | 0 | - | |
| Total revenues | Rs m | 4,612 | 827,370 | 0.6% | |
| Gross profit | Rs m | 2,030 | 214,093 | 0.9% | |
| Depreciation | Rs m | 540 | 154,916 | 0.3% | |
| Interest | Rs m | 1,048 | 39,794 | 2.6% | |
| Profit before tax | Rs m | 486 | 19,383 | 2.5% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 77 | -3,084 | -2.5% | |
| Profit after tax | Rs m | 409 | 22,467 | 1.8% | |
| Gross profit margin | % | 44.4 | 25.9 | 171.8% | |
| Effective tax rate | % | 15.9 | -15.9 | -99.7% | |
| Net profit margin | % | 9.0 | 2.7 | 329.9% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 2,415 | 462,003 | 0.5% | |
| Current liabilities | Rs m | 9,077 | 336,851 | 2.7% | |
| Net working cap to sales | % | -145.9 | 15.1 | -964.5% | |
| Current ratio | x | 0.3 | 1.4 | 19.4% | |
| Inventory Days | Days | 65 | 84 | 77.9% | |
| Debtors Days | Days | 71 | 93 | 76.0% | |
| Net fixed assets | Rs m | 8,333 | 160,496 | 5.2% | |
| Share capital | Rs m | 61 | 441 | 13.9% | |
| Net worth | Rs m | 3,504 | 895,063 | 0.4% | |
| Long term debt | Rs m | 461 | 966,060 | 0.0% | |
| Total assets | Rs m | 13,755 | 2,400,907 | 0.6% | |
| Interest coverage | x | 1.5 | 1.5 | 98.4% | |
| Debt to equity ratio | x | 0.1 | 1.1 | 12.2% | |
| Sales to assets ratio | x | 0.3 | 0.3 | 96.3% | |
| Return on assets | % | 10.6 | 2.6 | 408.6% | |
| Return on equity | % | 11.7 | 2.5 | 465.1% | |
| Return on capital | % | 38.7 | 3.2 | 1,217.1% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 1,049 | 171,928 | 0.6% | |
| From Investments | Rs m | -54 | -88,868 | 0.1% | |
| From Financial Activity | Rs m | -1,011 | -80,094 | 1.3% | |
| Net Cashflow | Rs m | -20 | 1,424 | -1.4% | |
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 73.42 Rs / USD
Compare PANACEA BIOTECH With: ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
Compare PANACEA BIOTECH With: ELDER PHARMA ALEMBIC PHARMA VENUS REMEDIES FRESENIUS KABI ONCO. SANOFI INDIA
Today's Market
Sensex Ends 447 Points Higher; Automobile & IT Stocks Rally(Closing)
Indian share markets witnessed buying interest during closing hours and ended today's volatile session higher.
Related Views On News
PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)
Mar 27, 2019 | Updated on Mar 27, 2019Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.
More Views on NewsMost Popular
It's the Beginning of a New Bull Phase in Smallcaps (Profit Hunter)
Feb 24, 2021Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
Make Rs 5,000 Per Day Trading the Market (Fast Profits Daily)
Feb 25, 2021In this video, I'll show you how to get started on the path to daily trading profits.
I Believe the Investment of the Year Will Be...
Feb 19, 2021In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.
The Hidden Tesla in My Great Indian Wealth Project (Profit Hunter)
Feb 23, 2021An Indian company founded three decades ago in a garage caught my attention...
More
